儿童严重创伤氨甲环酸临床试验(TIC-TOC):一项先导性随机对照试验的研究方案
TIC-TOC是一项在美国4个儿童一级创伤中心开展的多中心先导性随机对照试验,受试者为严重创伤合并躯干或脑出血性损伤的儿童,随机分为TXA剂量A组、剂量B组或安慰剂组。研究旨在评估开展确证性临床试验的可行性,并收集全球功能、工作记忆、输血量、颅内出血进展、凝血生物标志物及不良事件等结局的初步数据。
要点
- TXA在成人创伤性出血中改善生存,但在严重创伤儿童中尚未经临床试验评价。
- 受试儿童按损伤类型分层随机接受两种TXA剂量方案或安慰剂。
- 主要收集功能、认知、输血量、影像学进展、凝血标志物及安全性数据。
核心结论
- 该多中心先导试验将为评价TXA在严重创伤合并躯干和/或脑出血性损伤儿童中的获益提供重要初步数据,并评估开展确证性临床试验的可行性。
研究设计与样本
- 研究为多中心先导性随机对照试验,在4个儿童一级创伤中心开展。
- 受试者为严重创伤且有出血性躯干或脑损伤证据的儿童。
- 受试者按损伤类型(出血性脑损伤、出血性躯干损伤、出血性脑与躯干联合损伤)进行置换区组随机化,分配至三个治疗组之一。
关键数值与推荐
- TXA剂量A:20分钟内给予15 mg/kg负荷剂量,随后以2 mg/kg/hr输注8小时。
- TXA剂量B:20分钟内给予30 mg/kg负荷剂量,随后以4 mg/kg/hr输注8小时。
- 第三组为安慰剂。
- 结局指标包括PedsQL与GOS-E Peds评估的全球功能、数字广度测试的工作记忆、初始48小时内输血总量、24小时颅内出血进展、凝血生物标志物及不良事件(尤其血栓栓塞事件和癫痫发作)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trauma is the leading cause of morbidity and mortality in children in the United States. The antifibrinolytic drug tranexamic acid (TXA) improves survival in adults with traumatic hemorrhage, however, the drug has not been evaluated in a clinical trial in severely injured children. We designed the Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC) trial to evaluate the feasibility of conducting a confirmatory clinical trial that evaluates the effects of TXA in children with severe trauma and hemorrhagic injuries. METHODS: Children with severe trauma and evidence of hemorrhagic torso or brain injuries will be randomized to one of three arms: (1) TXA dose A (15 mg/kg bolus dose over 20 min, followed by 2 mg/kg/hr infusion over 8 h), (2) TXA dose B (30 mg/kg bolus dose over 20 min, followed by 4 mg/kg/hr infusion over 8 h), or (3) placebo. We will use permuted-block randomization by injury type: hemorrhagic brain injury, hemorrhagic torso injury, and combined hemorrhagic brain and torso injury. The trial will be conducted at four pediatric Level I trauma centers. We will collect the following outcome measures: global functioning as measured by the Pediatric Quality of Life (PedsQL) and Pediatric Glasgow Outcome Scale Extended (GOS-E Peds), working memory (digit span test), total amount of blood products transfused in the initial 48 h, intracranial hemorrhage progression at 24 h, coagulation biomarkers, and adverse events (specifically thromboembolic events and seizures). DISCUSSION: This multicenter trial will provide important preliminary data and assess the feasibility of conducting a confirmatory clinical trial that evaluates the benefits of TXA in children with severe trauma and hemorrhagic injuries to the torso and/or brain. TRIAL REGISTRATION: ClinicalTrials.gov registration number: NCT02840097 . Registered on 14 July 2016.
引用
- Nishijima DK, VanBuren J, Hewes HA, et al. Traumatic injury clinical trial evaluating tranexamic acid in children (TIC-TOC): study protocol for a pilot randomized controlled trial. Trials. 2018. PMID: 30376893. doi:10.1186/s13063-018-2974-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。